GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Modus Therapeutics Holding AB (FRA:99Z) » Definitions » Retained Earnings

Modus Therapeutics Holding AB (FRA:99Z) Retained Earnings : €-28.91 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Modus Therapeutics Holding AB Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Modus Therapeutics Holding AB's retained earnings for the quarter that ended in Sep. 2024 was €-28.91 Mil.

Modus Therapeutics Holding AB's quarterly retained earnings declined from Mar. 2024 (€-28.32 Mil) to Jun. 2024 (€-28.81 Mil) and declined from Jun. 2024 (€-28.81 Mil) to Sep. 2024 (€-28.91 Mil).

Modus Therapeutics Holding AB's annual retained earnings increased from Dec. 2021 (€-27.38 Mil) to Dec. 2022 (€-27.24 Mil) but then declined from Dec. 2022 (€-27.24 Mil) to Dec. 2023 (€-28.37 Mil).


Modus Therapeutics Holding AB Retained Earnings Historical Data

The historical data trend for Modus Therapeutics Holding AB's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Modus Therapeutics Holding AB Retained Earnings Chart

Modus Therapeutics Holding AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
-23.68 -24.60 -27.38 -27.24 -28.37

Modus Therapeutics Holding AB Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -26.47 -28.37 -28.32 -28.81 -28.91

Modus Therapeutics Holding AB Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Modus Therapeutics Holding AB  (FRA:99Z) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Modus Therapeutics Holding AB Business Description

Traded in Other Exchanges
Address
Olof Palmes gata 29 IV, Stockholm, SWE, 111 22
Modus Therapeutics Holding AB is a Swedish clinical biotechnology company developing a treatment for sepsis, endotoxemia, severe malaria, and other disorders with severe systemic inflammation as well as states of anemia, related to chronic inflammation such as kidney diseases through its patented polysaccharide sevuparin. The drug candidate sevuparin has the opportunity to benefit patients and save large healthcare costs.

Modus Therapeutics Holding AB Headlines

No Headlines